Toronto, 27 September 2020 –
WHAT Before the United Nations Biodiversity Summit, this large-scale occasion jointly organized through WWF brings together global leaders from more than 20 countries, as well as Prime Minister Justin Trudeau, who will dedicate themselves to strengthening global ambition for biodiversity and inspiring other leaders to match their collective ambition for nature , the weather and people. TO WORLD EMERGENCY Nature is in crisis. Science tells us that human activities destroy and degrade the same herbal systems that affect our fitness and livelihood. Targeted conservation, nature-based solutions, formal protections and administration, and millions of movements across Americans and communities across Canada and around the world are needed to address wildlife and biodiversity loss and climate change.
WHEN Monday, September 28, 2020, 9:00 a. m. to 10:30 a. m. EDT. The occasion will also come with a live verbal exchange between SE Justin Trudea, Prime Minister of Canada; That. Carlos Alvarado Quesada, President of Costa Rica, and SE Erna Solberg, Prime Minister of Norway.
Illinois. Mr Alexander van der Bellen, President of Austria
That. Ms. Jeanine Ez, President of the Plurinational State of Bolivia
That. Mr. Ivon Duque Marquez, President of Colombia
Illinois. Carlos Alvarado Quesada, President of Costa Rica
Illinois. Mr. Conos Eder, President of Hungary
Eso. Sr. Uhuru Kenyatta, President of the Republic of Kenya
Eso. Sr. Ion Chicu, Prime Minister of the Republic of Moldova
Eso. Sr. Laurentino Cortizo Cohen, President of the Republic of Panama
Eso. Sr. Martín Vizcarra Cornejo, President of the Republic of Peru
His Highness Serena Prince Albert II, Monaco
Eso. Sr. David Kabua, President of the Republic of the Marshall Islands
Illinois. Danny Faure, Seychelles president
That. Borut Pahor, President of the Republic of Slovenia
That. Dr. Lotay Tshering, MBBS, MD, Prime Minister of the Kingdom of Bhutan
Illinois. Mr. Justin Trudeau, Prime Minister of Canada
Eso. Sr. Andrej Babio, Prime Minister of the Czech Republic
Illinois. Xavier Bettel, Prime Minister of Luxembourg
IL. MK P. Sharma Oli, Prime Minister of the Federal Democratic Republic of Nepal
Illinois. Erna Solberg, Prime Minister of Norway
Hon. Imran Khan, Prime Minister of Pakistan
He. Boris Johnson, UK Prime Minister
And he. Ursula von der Leyen, President of the European Commission
Other heads of state and government, as well as senior UN officials, will be confirmed. The occasion will also come with statements from leaders from across society and the business community. MEDIA AND PORTE-PAROLE A press release, under embargo at 00:01 BST (GMT 1) on 28 September 2020, will be made available to the media before the occasion. Contact: [email protected].
TO JOIN The event of leaders for nature and people is open to the media. He is cordially invited to see the occasion. Array. La occasion will be transmitted on this page: https://www. learningfornature. org/en/topic/session-1-a -response-global-to-our-emergency-planetary-protect-our-network-of-security /
At the Global Fund for Nature in Canada, WWF-Canada is creating responses to demanding environmental situations that are of the utmost importance to Canadians. We paint in exclusive and ecologically vital places to unite nature and humans, because we are all wild animals. For more information, scale http://www. wwf. ca
For public protection due to bad weather and strong winds, PG
ROSEN, GLOBAL INVESTOR COUNSEL, reminds investors of Wrap Technologies, Inc. A deadline for the action of elegance of values; Encourage investors with losses of more than $100,000 to touch the company – WRTC
A recent survey of Marriott Bonvoy meetings and occasions in china’s Asia-Pacific region (APEC) indicates:
SINGAPORE, September 28, 2020 / PRNewswire / – As companies begin to adapt to a new normal, meetings and occasions are slowly returning, but with many points to consider in a survey conducted through Marriott Bonvoy, Marriott International’s program, about meeting expectations and occasions in the new normal, some respondents plan to continue with offline occasions (50%), however, there is a high volume of fear about government regulations (45%) and the criteria for the protection and hygiene of the premises (30%), among others.
The survey reached more than 500 respondents, adding event and meeting planners, administrative staff and executive positions in various sectors of APEC.
“The existing ‘new world’ in which we revel through this pandemic has forced us to live a different and superior delight for consumers in other sectors and markets,” said Rajeev Menon, President, Asia-Pacific (excluding Greater China), Marriott International. “We see that the recreational is slowly returning, followed by business trips and then groups. And thanks to our Commitment to Cleanliness initiative, we are able to welcome visitors to our hotels around the world, providing them with a safe environment. that aligns with specialized protocols and adheres confidently. “
New content on the virtual platform for events
To address some of these concerns, Marriott International is introducing new content, a virtual platform for meetings and events that aims to redefine processes and reinvent spaces guided by cleaning experts and more productive practices to help hosts, organizers, and participants plan and execute meetings. and attach with confidence. This follows the company’s announcement of its commitment to the Clean and Comprehensive Cleaning Council.
Meeting planners now have access to a number of new documents, which add data videos, consumer testimonials, and resources that provide more context and data to design successful occasions in today’s environment. The tools, available in MarriottBonvoyEvents. com, illustrate Marriott International’s technique for delivering high-quality assembly reports across its portfolio of hotels and hotels.
Connect with confidence: Marriott’s new assembly and occasion protocols for the highest hygiene standards
Thanks to the survey, 70% of respondents prefer national destinations. With Marriott Connect with Confidence hygiene protocols in mind, Marriott International homes in the region will offer virtual answers to event planners who cannot or prefer not to travel. With those answers, event planners might not have to be on site to get a review of homes and meeting rooms. On-demand hand masks and disinfectants will be manufactured through assembly planners and attendees to alleviate hygiene concerns. Regular temperature controls will also be implemented for all participants upon arrival at the houses. In addition, all affiliates must wear masks. Through virtual planning, consultations, pre-convention assemblies, and site visits can be adapted to include information sessions on fitness and protection.
The rooms can accommodate other seating capabilities thanks to a flexible redesign of the mounting furniture. Furniture is kept at a distance to meet social distance requirements. If so, hybrid live or virtual mounts must be have through live streaming features. minimize social contact.
Meals and breaks are spaced for other occasions to mingle with participants from other occasions. A wide variety of F options
Raise offerings for assemblies and occasions as one of the leaders
While offline occasions may be a popular option, 36% of respondents plan to host more hybrid occasions; this means combining physical and live streaming elements to maximize reach, through geographic constraints.
Supporting such hybrid occasions requires significant resources and attention to detail. Most Marriott International locations have mandatory generation and have experienced the reserve to empower businesses on their hybrid occasions. Events held in a hotel can help create a well-balanced environment. and environment for live and online audiences. Dedicated on site can also help temporarily satisfy the desires of any occasion and make sure the event unfolds elegantly.
Marriott Bonvoy offers 3 times more rewards for eligible meetings and occasions booked at attractive hotels in the Asia-Pacific region. For more information, https://marriottoccasionsasia. com/tripletreats/
Marriott International, Inc. (NASDAQ: MAR) was founded in Bethesda, Maryland, USA. Usa, E includes a portfolio of more than 7,400 households with 30 major brands spanning 135 countries and territories. The company offers Marriott Bonvoy ™, its highly award-winning program. For more information, visit our online page at www. marriott. com, and for the latest corporate news, visit www. marriottnewscenter. com. us on Facebook and @MarriottIntl on Twitter and Instagram.
Logo – https://photos. prnasia. com/prnh/20200813/2884854-1logo?lang=0
Related links:
http://www. marriott. com
SAN FRANCISCO and SUZHOU, China, September 28, 2020 / PRNewswire / – Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and markets high-quality medicines for the remedy of oncology, metabolic diseases, autoimmune diseases and other primary diseases, announced today the effects of a randomized and open phase 3 examination in China. The ORIENT-32 trial comparing TYVYT® (injection of sintylimab) in mixture with BYVASDA® (bevacizumab biosimilar injection, or IBI305) as a first-line remedy for complex hepatocellular carcinoma (CHC) met the predefined assessment criteria progression-free survival (SSP)) and overall survival (SG) in an intermediate analysis. This is the first phase 3 clinical trial that used a cure combined with PD-1 inhibitor that met the number one assessment criterion in the chC complex’s first-line remedy.
Based on intermediate research conducted through the Independent Data Monitoring Committee (IDMC), TYVYT® (injection of sintylimab) in mixture with BYVASDA® (bevacizumab biosimilar injection) demonstrated a statistically significant improvement in SSP and SG compared to sorafenib. TYVYT® (sintilimab injection) and BYVASDA® (injectable biosimilar bevacizumab) in this trial was consistent with studies reported in the past, and no new signs of protection were identified. This knowledge will be presented at an upcoming medical conference. Based on the IDMC recommendation, Innovent will review these effects with the National Medical Products Administration (NMPA) Drug Evaluation Center (CRC) in China.
ORIENT-32 Principal Investigator Professor Fan Jia from Fudan University Zhongshan Hospital, said: “In China, HCC is the fourth highest non-unusual malignancy with the highest death rate at the moment. higher. More than part of the world’s new fatal HCC cases occur in China each year. Currently, sorafenib, lenvatinib, and chemotherapy are the main remedies for HCC as a first-line remedy in China, with very limited efficacy. Approximately 85% of patients with HCC in China have a history of HBV infection, which is a very different feature of HCC in European and American countries. Therefore, further clinical studies on the HCC remedy are of great importance in China. The ORIENT-32 test showed that TYVYT® (sintilimab injection), mixed with BYVASDA® (biosimilar bevacizumab injection), would possibly prolong PFS and OS in the first-line HCC remedy. Despite the COVID-19 pandemic, all exam investigators worked to triumph over many demanding situations to continue this trial in an effort to bring new hope to HCC patients. “
Dr Hui Zhou, Vice President and Director of Cancer Strategy and Medical Sciences at Innovent, said: “TYVYT® is the only anti-PD-1 monoclonal antibody included in the new catalog of China’s national list of reimbursement drugs. approved through NMPA on 24 December 2018 for the treatment of recurrent or refractory old Hodgkin lymphoma after two or more lines of systemic chemotherapy. Metastatic lung cancer and colorectal cancer in China. The effects of the ORIENT-32 test demonstrate the potential of TYVYT® in mixture with BYVASDA® to treat patients with complex frontline HCC. We hope that this clinical trial will prospectively provide a better remedy option for physicians and patients with CHC We would like to express our sincere thanks to all patients and researchers who participated in the ORIENT-32 exam. o Continuous contributions have been made through the joint efforts of researchers and the examination team, despite the demanding situations and with the effects of the COVID-19 pandemic.
About the ORIENT-32 trial
ORIENT-32 is a phase 3 multicenter study, randomized, open, to compare the efficacy and protection of TYVYT® (injectable sintylimab) in mixture with BYVASDA® (bevacizumab biosimilar for injection) compared to sorafenib in the first-line remedy of patients with complex hepatocellular carcinoma (ClinicalTrials. gov, NCT 03794440). The number one valuation criteria are progression-free survival (SSP) and overall survival (GS) evaluated through an independent radiographic review committee (IRRC) founded on RECIST v1. 1.
Enrolled patients were randomly assigned 2:1 to obtain TYVYT® (sintylimab injection) in accordance with BYVASDA® (bevacizumab biosimilar injection) or sorafenib, until disease progression, unacceptable toxicity, withdrawal of consent, death or other reasons discussed in the protocol, depending on what happens first.
About Hepatocellular Carcinoma (CHC)
Primary liver cancer (LPC) is a common malignancy of the digestive formula worldwide, of which a portion of new cases and deaths occur in China. The main pathological types of liver cancer are hepatocellular carcinoma (CHC), which accounts for 85 to 90 percent, and a small number of cases of intrahepatic cholangiocarcinoma (CCD) and HCC-ICC combined liver cancer. In China, CHC is basically produced through hepatitis B virus (HBV) infection and/or hepatitis C virus (HCV).
About TYVYT® (Sintilimab Injection)
TYVYT® (sintilimab injection) is a state-of-the-art drug with global quality criteria developed jointly through Innovent and Lilly in China. TYVYT® has obtained marketing approval through NMPA for recurrent or refractory classic Hodgkin lymphoma remedy after two or more systemic treatment lines. chemotherapy and has been included in the 2019 rules of the Chinese Society of Clinical Oncology for Malignant Lymphoid Tumors. TYVYT® is the only PD-1 inhibitor to be included in the new NRDL catalog in November 2019.
In April 2020, the NMPA accepted the application for a new drug for TYVYT® in mixture with ALIMTA® (pémétrexed) and platinum chemotherapy as a first-line remedy for non-small non-scaly moving lung cancer (NPCC). 2020, TYVYT® related to GEMZAR® (gemcitabine for injection) and platinum chemotherapy met the number one tithe criterion predefined in the Orient-12 Phase 3 test as a first-line remedy in patients with locally complex or metastatic epidermoid NPCC. the number one assessment criterion of the ORIENT-2 test as a second-line remedy in patients with complex or metastatic squamous mobile carcinoma In August 2020, NMPA accepted SNDA for TYVYT® in mixture with GEMZAR® (gemcitabine for injection) and platinum chemotherapy as a first-line remedy in patients with metastatic or locally complex NPCC epidermoid.
TYVYT is a type of G4 monoclonal immunoglobulin antibody, which binds to PD-1 molecules on the surface of T cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway and reactivates T cells to destroy cancer cells. Lately he has conducted more than 20 clinical studies with TYVYT® to compare its protection and efficacy in a wide range of cancer indications worldwide, adding more than 10 clinical records or key trials.
About BYVASDA® (bevacizumab biosimilar for injection)
BYVASDA® (IBI305) is a biosimilar to bevacizumab and a recombinant humanized anti-VEGF monoclonal antibody. Vascular endothelial expansion (VEGF) is a vital thing in angiogenesis that is expressed superiorly through endothelial motives in maximal human tumors. An anti-VEGF antibody selectively binds VEGF with maximum affinity and blocks its binding to VEGF receptors on the surface of vascular endothelial mobiles, thus inhibiting signaling pathways such as PI3K-Akt / PKB and Ras-Raf-MEK- ERK. BYVASDA® produces antitumor effects by inhibiting the expansion, proliferation and migration of vascular endothelial motifs, blocking angiogenesis, cutting vascular permeability, blocking the blood supply to tumor tissue, inhibiting the proliferation and metastasis of tumor motives and inducing the apoptosis in tumor motives. Since the launch of bevacizumab, it has been approved for the treatment of patients with multiple malignant tumors worldwide, adding non-small mobile lung cancer, metastatic colorectal cancer, glioblastoma, renal carcinoma, cervical cancer and ovarian epithelium, fallopian tubes. Fallopian or various a peritoneal cancer. The efficacy and protection of bevacizumab have been well identified throughout the world.
About Innovent
Inspired by the spirit of “Start with Integrity, Succeed through Action,” Innovent’s project is to expand and market high-quality biopharmaceutical products that are affordable for ordinary people. Founded in 2011, Innovent is committed to expanding, producing and marketing high-quality biopharmaceutical products. -quality medicines for the treatment of cancer, metabolic diseases, autoimmune diseases and other primary diseases. On 31 October 2018, Innovent was included in the main index of the Hong Kong Limited Stock Exchange with the inventory market code: 01801. HK.
Since its inception, Innovent has developed a built-in multifunctional platform that includes R
Innovent has built a foreign team with experience in the progression and marketing of complex biological drugs, and the company has also established strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Alector, MD Anderson Cancer Center, Hanmi and foreign partners. information, visit: www. innoventbio. com.
Note: TYVYT® (sintilimab injection) is an approved product in the United States. BYVASDA® (bevacizumab biosimilar for injection) is an approved product in the United States. SULINNO® (adaumlimab biosimilar for injection) is an approved product in the United States.
TYVYT® (Sintylimab Injection, Innovent) BYVASDA® (biosimilar injection of bevacizumab, Innovent) SULINNO® (biosimilar injection of adalimumab, Innovent) ALIMTA® and GEMZAR® are registered property or authorized by Eli and Lilly.
Related links:
http://www. innoventbio. com
BEIJING, September 28, 2020 / PRNewswire / – SANY has presented a full battery edition of its mixing trucks, which are expected to be the highlight in CHINA 2020 bauma.
The lightweight model is supplied with permanent magnet synchronous motors with a maximum force of 350 kW and a torque of 2800 N m, outperforming diesel-powered vehicles. High-force LFP batteries provide sufficient force resources for movement of vehicle and mixing activities, allowing a nominal NEDC diversity of 250 km. What’s more is our concept of security. We’ve partnered with a world-leading battery supplier to build the power source with thermal control technology, a non-return design, and a chimney cover system. .
Other vehicle features come with self-heating service such as in a low temperature environment and a complex high temperature cooling system, so the truck is flexible in a wide variety of operating conditions. In addition, Truck Line, an IoT platform committed to SANY vehicles, provides productivity-enhancing features such as real-time monitoring, functionality analysis, and remote diagnostics.
These battery-packed mixing trucks are not only prototypes, but have been delivered and put into service for our strategic partners in China. The world is turning green. SANY’s battery-powered responses help and help our consumers gain their acceptance as true in the face of growing emissions regulations.
About SANY Group
Founded in 1989, SANY is a global manufacturer of complex structures and mining equipment, port and oil drilling machinery and renewable wind power systems. To date, SANY has built 25 production bases, 12 sales regions and more than one hundred offices with more than 400 dealers and 8,000 suppliers worldwide. In China, SANY has created seven trade parks in Beijing, Changsha, Shanghai, Shenyang, Zhuhai, Kunshan and Urumqi. With global R centers
A recent survey of meetings and occasions conducted through Marriott Bonvoy in Asia-Pacific China (APEC) indicates: 50% of respondents
BEIJING, September 28, 2020 / PRNewswire / – SANY has presented a full battery edition of its concrete trucks, which array is expected. .
SAN FRANCISCO and SUZHOU, China, September 28, 2020 / PRNewswire / – Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical matrix.
TAIPEI, TAIWAN – Media OutReach – September 28, 2020 – The First Harmony International Forum
SINGAPORE – Media OutReach – 28 September 2020 – Launching websites in ASEAN countries such as Indonesia, Singapore, Hong Kong and Array.
SINGAPORE – Media OutReach – September 28, 2020 – Dream Career Builder introduces a new “Work from Home” feature in its meetArray search function.
Bernstein Liebhard, a nationally renowned investor rights company, is investigating imaginable allegations of securities fraud on behalf of Array shareholders.
SHANGHI, September 28, 2020 / PRNewswire / – InventisBio, a biotechnology company in clinical stage committed to the progression of Array. .
NEW YORK, September 28, 2020 / PRNewswire / – OTC Markets Group Inc. (OTCQX: OTCM), money market operator for 11,000 US and international matrices.
FOSTER CITY, Calif. Y HANGZHOU, China, 27 September 2020 – Apollomics, Inc. , a state-of-the-art biopharmaceutical company dedicated to the discovery of Array.
Mandatory cookies are surely for the proper functioning of the site. This category includes only cookies that provide the fundamental capacity and security features of the website. These cookies do not purchase any non-public information.